BioInvest Israel 2012: Local & Global Pharma, Medtech and Finance Companies Meet to Talk Business
News Jan 13, 2012
BioInvest Israel™ 2012 that will take place on March 5 - 6, 2012, and is another initiation from The T.B.N. Group. In today's challenging market the Israeli Biomedical industry is becoming ever more attractive to global companies and investors looking for concrete business dealings such as: Mergers, Acquisitions, Creative partnering models, Alternative finance and Investments, In- out licensing, IPO, Exit and other deals that will increase the value of their companies.
"The reasons our partnering conference is getting much attention and interest " said Sigal Weisswasser President of The T.B.N Group " is due to our profound understanding of the industry's needs along with our active involvement and connections that put together a special blend of local and global Medtech , Pharma and Finance companies ( Vc's, Insurance groups, banks ..) that look for one another especially these days.
"In addition" said Weisswasser "our very successful cooperation with EBD Group (the global partnering event organizer) whom we represent in Israel for many years now, allow us to offer a different kind of top of the line international partnering event using the exceptional partneringOne software to maximize the pre- qualified meeting opportunities to all participants".
Sigal also added " BioInvest Israel is another exciting opportunity for us to place Israel as a center for business dealings within the innovative life science industry, and being a strong believer in my industry, It is important for me that companies from around the world will come over here to meet us in person and learn that we are so different than the way we appear on the news. They will find an interesting and colorful country comprises of nice and warm, open and creative people that look forward exploring business ventures with".
To support its statement, BioInvest Israel will offer the event attendees a unique tour in Northern Israel on March 7th "Walking the path of History" that is sponsored by the City of Haifa and getting much interest.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.READ MORE
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.